AB Science S.A. (ABSCF) Discusses Clinical Update on AB8939 Combined With Venetoclax for Refractory and Relapsed AML With Poor Genetics Transcript

Core Points - The web conference organized by AB Science aims to provide an update on the clinical development of their lead drug, AB8939 [1][3] - The presentation will be technical in nature, focusing on the progress of AB8939, which is currently in Phase I of clinical trials [3] Group 1 - Alain Moussy serves as the Co-Founder, Chairman, President, CEO, MD, and Scientific Director of AB Science [1] - The conference features notable experts including Nicholas Short, Olivier Hermine, and Christian Auclair, who contribute to the scientific and clinical aspects of the drug development [2] - Laurent Guy, the Chief Financial Officer, will address questions from participants at the end of the presentation [2]